AP3595A - Novel gp41 antigens - Google Patents

Novel gp41 antigens

Info

Publication number
AP3595A
AP3595A AP2011005854A AP2011005854A AP3595A AP 3595 A AP3595 A AP 3595A AP 2011005854 A AP2011005854 A AP 2011005854A AP 2011005854 A AP2011005854 A AP 2011005854A AP 3595 A AP3595 A AP 3595A
Authority
AP
ARIPO
Prior art keywords
antigens
novel
Prior art date
Application number
AP2011005854A
Other languages
English (en)
Other versions
AP2011005854A0 (en
Inventor
Sylvain Fleury
Nicolas Mouz
Marie-Gaelle Roger
Original Assignee
Mymetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymetics Corp filed Critical Mymetics Corp
Publication of AP2011005854A0 publication Critical patent/AP2011005854A0/xx
Application granted granted Critical
Publication of AP3595A publication Critical patent/AP3595A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2011005854A 2009-02-06 2010-02-08 Novel gp41 antigens AP3595A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20221509P 2009-02-06 2009-02-06
PCT/EP2010/051522 WO2010089400A1 (en) 2009-02-06 2010-02-08 Novel gp41 antigens

Publications (2)

Publication Number Publication Date
AP2011005854A0 AP2011005854A0 (en) 2011-08-31
AP3595A true AP3595A (en) 2016-02-17

Family

ID=42104745

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005854A AP3595A (en) 2009-02-06 2010-02-08 Novel gp41 antigens

Country Status (12)

Country Link
US (1) US8765137B2 (xx)
EP (1) EP2393510A1 (xx)
KR (1) KR101756202B1 (xx)
CN (1) CN102307592A (xx)
AP (1) AP3595A (xx)
BR (1) BRPI1008671A2 (xx)
CA (1) CA2750058C (xx)
EA (1) EA021191B1 (xx)
MX (1) MX2011007703A (xx)
UA (1) UA108469C2 (xx)
WO (1) WO2010089400A1 (xx)
ZA (1) ZA201105396B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102254420B1 (ko) 2019-09-02 2021-05-21 박무순 약용 및 식용 천연물 복합 발효액을 유효성분으로 함유하는 항균 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010033A1 (en) * 2003-07-30 2005-02-03 Mymetics Corporation New soluble and stabilized trimeric form of gp41 polypeptides
WO2006117586A1 (en) * 2005-05-02 2006-11-09 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
WO2007099446A2 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0538437B1 (en) 1991-05-08 1999-08-04 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
BR0303362A (pt) * 2002-03-06 2005-07-19 Univ Arizona State Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
EA008497B1 (ru) 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
EP1447080A1 (en) 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
WO2005001033A2 (en) 2003-05-22 2005-01-06 The Cleveland Clinic Foundation Tolerance induction and maintenance in hematopoietic stem cell allografts
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
EP1805204A2 (en) 2005-09-14 2007-07-11 Novetide Ltd. Process for production of bivalirudin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010033A1 (en) * 2003-07-30 2005-02-03 Mymetics Corporation New soluble and stabilized trimeric form of gp41 polypeptides
WO2006117586A1 (en) * 2005-05-02 2006-11-09 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
WO2007099446A2 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATOBA N. ET AL.: "Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate", VACCINE, ELSEVIER LTD, GB LNKD-DOI:10.1016/J. VACCINE. 2006.03.045, vol. 24, no. 23, 5 June 2006 (2006-06-05), pages 5047-5055, XP025151330 *
MATOBA NOBUYUKI ET AL.: "Transcytosis-blocking Abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes", CURRENT HIV RESEARCH, vol. 6, no. 3, May 2008 (2008-05), pages 218-229, XP009132624 *

Also Published As

Publication number Publication date
EP2393510A1 (en) 2011-12-14
KR101756202B1 (ko) 2017-07-10
CN102307592A (zh) 2012-01-04
KR20110125224A (ko) 2011-11-18
EA201190096A1 (ru) 2013-02-28
CA2750058C (en) 2017-11-28
AU2010210071A1 (en) 2011-07-21
BRPI1008671A2 (pt) 2016-03-08
CA2750058A1 (en) 2010-08-12
ZA201105396B (en) 2012-04-25
US8765137B2 (en) 2014-07-01
UA108469C2 (xx) 2015-05-12
AP2011005854A0 (en) 2011-08-31
EA021191B1 (ru) 2015-04-30
US20110311615A1 (en) 2011-12-22
MX2011007703A (es) 2011-09-28
WO2010089400A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
ZA201104545B (en) Anti-siglec-15 antibody
IL217008A0 (en) Vaccine
EP2429585A4 (en) VACCINE IMMUNOTHERAPY
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
IL225667A0 (en) A new antigen
GB0905570D0 (en) Combined vaccines
GB0920324D0 (en) Antibodies
EP2426149A4 (en) ANTI-CADHERIN ANTIBODY
HK1170745A1 (en) Antibodies against il-17br il-17br
GB201006165D0 (en) Vaccine
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB201000522D0 (en) Vaccine
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
ZA201105357B (en) Splitting gp41
EP2424892A4 (en) DC-STAMP ANTIBODY
IL217194A0 (en) Vaccine
AP3595A (en) Novel gp41 antigens
GB0908945D0 (en) Antibodies
GB0908885D0 (en) Mycobacterial antigens
GB0911712D0 (en) Antibody